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Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and
apixaban for their relative efficacy and safety against each other.
Background Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinical trials of stroke
prevention in atrial fibrillation (AF) are now available for the oral direct thrombin inhibitor, dabigatran etexilate,
in 2 doses (150 mg twice daily [BID], 110 mg BID), and the oral Factor Xa inhibitors, rivaroxaban and apixaban.
A “head-to-head” direct comparison of drugs is the standard method for comparing different treatments, but in
the absence of such head-to-head direct comparisons, another alternative to assess the relative effect of differ-
ent treatment interventions would be to perform indirect comparisons, using a common comparator. Nonethe-
less, any inter-trial comparison is always fraught with major difficulties, and an indirect comparison analysis has
many limitations, especially with the inter-trial population differences and thus, should not be overinterpreted.
Methods Indirect comparison analysis was performed using data from the published trials.
Results There was a significantly lower risk of stroke and systemic embolism (by 26%) for dabigatran (150 mg BID)
compared with rivaroxaban, as well as hemorrhagic stroke and nondisabling stroke. There were no significant
differences for apixaban versus dabigatran (both doses) or rivaroxaban; or rivaroxaban versus dabigatran 110
mg BID in preventing stroke and systemic embolism. For ischemic stroke, there were no significant differences
between the new OACs. Major bleeding was significantly lower with apixaban compared with dabigatran 150 mg
BID (by 26%) and rivaroxaban (by 34%), but not significantly different from dabigatran 110 mg BID. There were
no significant differences between apixaban and dabigatran 110 mg BID in safety endpoints. Apixaban also had
lower major or clinically relevant bleeding (by 34%) compared with rivaroxaban. When compared with rivaroxaban,
dabigatran 110 mg BID was associated with less major bleeding (by 23%) and intracranial bleeding (by 54%). There
were no significant differences in myocardial infarction events between the dabigatran (both doses) and apixaban.
Conclusions Notwithstanding the limitations of an indirect comparison study, we found no profound significant differences in
efficacy between apixaban and dabigatran etexilate (both doses) or rivaroxaban. Dabigatran 150 mg BID was
superior to rivaroxaban for some efficacy endpoints, whereas major bleeding was significantly lower with dabiga-
tran 110 mg BID or apixaban. Only a head-to-head direct comparison of the different new OACs would fully an-
swer the question of efficacy/safety differences between the new drugs for stroke prevention in AF. (J Am Coll
Cardiol 2012;60:738–46) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.019Stroke is a devastating complication associated with atrial
fibrillation (AF), which is the most common sustained cardiac
rhythm disorder. Effective prevention of stroke requires oral
anticoagulation (OAC) therapy, and until recently, this was
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August 21, 2012:738–46 New Oral Anticoagulant Drugs in AFneed for regular monitoring, have led to the quest for new OACs
that would be safe and effective alternatives to warfarin (2).
Data for warfarin compared against the new OACs in
arge phase III clinical trials are now available for the oral
irect thrombin inhibitor, dabigatran etexilate, in 2 doses (150
g twice daily [BID], 110 mg BID) and the oral Factor Xa
nhibitors, rivaroxaban and apixaban (3–6). Apixaban also has
clinical trial against aspirin, among patients deemed
nsuitable for or who have refused warfarin (7).
The RE-LY (Randomized Evaluation of Long-Term
nticoagulant Therapy) trial compared 2 doses of dabiga-
ran etexilate against warfarin in AF patients with 1 or more
troke risk factors, and reported that dabigatran 110 mg
ID was noninferior to warfarin for the primary endpoint of
troke and systemic embolism, with 20% less major bleeding
vents (3). Following additional adjudication, some end-
oints from the original 2009 publication were updated in a
010 letter to the New England Journal of Medicine (4). The
ROCKET-AF (Rivaroxaban Once Daily Oral Direct Fac-
tor Xa Inhibitor Compared With Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation) trial studied a high-risk population of patients
with AF, and found that rivaroxaban 20 mg once daily
(OD) (with a dose adjustment of 15 mg OD for those with
moderate renal impairment) was noninferior to warfarin for
stroke and systemic embolism, with a similar rate of major
bleeding (5). The ARISTOTLE (Apixaban for Reduction
in Stroke and Other Thromboembolic Events in Atrial
Fibrillation) trial reported that apixaban 5 mg BID (with a
dose adjustment to 2.5 mg BID for patients with 2 of 3
criteria: age 80 years, body mass index 60 kg/m2, and
serum creatinine133 mol/l) was superior to warfarin (by
21%) for reducing stroke and systemic embolism, with 31%
fewer major bleeding events (6). All the drugs demonstrated
significantly less hemorrhagic stroke and intracranial hem-
orrhage, compared with warfarin. The outcome data from
these trials are summarized in Online Table 1.
Both dabigatran and rivaroxaban already have regulatory
approval and a license for stroke prevention in some
countries, and apixaban is anticipated to gain regulatory
approval in 2012. Thus, clinicians may have a number of
new OACs available, but would need information about
how these agents directly compare against each other in
terms of efficacy and safety. Head-to-head clinical trials of
these new OACs would require huge numbers of patients to
achieve statistical power for noninferiority, and may not be
viable options in the near future. In the absence of such
direct comparisons in large prospective randomized con-
trolled trials, another accepted alternative to assess the
relative effect of different treatment interventions would be
to perform indirect comparisons on the basis of the pub-
lished trials so far, using a common comparator (8). In the
case of the new OACs, warfarin was the comparator used in
common for all the main noninferiority trials.
The aim of the present study was to perform an indirect
comparison analysis of apixaban against dabigatran etexilate(2 doses) and rivaroxaban, as well
as rivaroxaban against dabigatran
etexilate (2 doses), for their rela-
tive efficacy and safety against
each other. Nonetheless, any inter-
trial comparison is always fraught
with major difficulties, and an indi-
rect comparison analysis has many
limitations, especially with the in-
tertrial population differences, and
thus should not be over-interpreted. However, this method is
a well-accepted analysis in the absence of head-to-head trials.
Methods
The main efficacy and safety endpoints from the RE-LY,
ROCKET-AF, and ARISTOTLE clinical trials were re-
viewed for comparability and consistency of definitions
(Online Table 1). RE-LY and ARISTOTLE were broadly
similar in patient demography (e.g., age, gender mix, etc.)
and baseline stroke risk (average CHADS2 score of 2.1). By
contrast, ROCKET-AF patients were slightly older (me-
dian age: 73 years), were at higher stroke risk (mean
CHADS2 score: 3.5), and 55% were a secondary prevention
population. The average time in therapeutic range values in
the warfarin-treated patients for RE-LY, ROCKET-AF,
and ARISTOTLE were 64%, 55%, and 62%, respectively.
RE-LY was conducted as an open trial, (prospective, randomized,
open-blinded endpoint evaluation, i.e., PROBE design), whereas
the other trials were double-blind trials.
All baseline characteristics, except for age and average
CHADS2 score, were described with proportions/risk for
eported characteristics. The studies were then compared in
erms of risk differences and corresponding 95% confidence
ntervals, which was considered a relevant measure for the
uantification of the difference between trials. Comparison
f average CHADS2 score between the trials was a standard
2-sample comparison for normal data. Age differences were
not compared statistically due to differences in reporting
between the trials.
Our endpoints of interest for this mixed treatment
comparisons focused on the primary efficacy and safety
endpoints. For all trials, the primary efficacy endpoint was
“all stroke and systemic embolism,” whereas the primary
safety endpoint for all trials, except ROCKET-AF, was
major bleeding by International Society on Thrombosis and
Haemostasis (ISTH) criteria (3–7). In ROCKET-AF, the
primary safety endpoint was the composite of “major and
clinically relevant non-major bleeding,” results of which
were not reported in RE-LY.
“Life-threatening bleeding” was not reported in the
ARISTOTLE trial. Also, “major or clinical relevant non-
major bleeding” was not reported in RE-LY, but included
in ARISTOTLE. The combined endpoint “ischemic or uncer-
Abbreviations
and Acronyms
AF  atrial fibrillation
BID  twice daily
MI  myocardial infarction
OAC  oral anticoagulation
therapy
OD  once dailytain type of stroke” was not reported for ROCKET-AF, but the
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New Oral Anticoagulant Drugs in AF August 21, 2012:738–46result from ischemic stroke was used because the reported fre-
quencies of uncertain stroke types were very low.
Secondary endpoints of interest were also compared in
this study, including individual components of the primary
efficacy and safety endpoints. Also, there was reported a
numerical increase in myocardial infarction (MI) events in
the RE-LY trial (3,4), and some debate has arisen as to
whether this is due to dabigatran or reflects a protective
effect of warfarin (9). Finally, the endpoint of pulmonary
embolism was not reported in ROCKET-AF.
For all endpoints found appropriate for analysis, the re-
ported hazard rate ratio and confidence intervals were extracted
from the study publications. In the RE-LY study, the results
were reported as risk ratio and confidence intervals. Also, an
update was published for the RE-LY study (4), and the data
from this update was used for our analysis. Results from
intention-to-treat analyses were used throughout.
Statistical methods. We used the so-called Bucher
ethod (10) for indirect comparisons using a common
omparator, which is a statistical method for estimating
azard rate ratio and corresponding uncertainty. The
ethod is recommended (8) as a preferred method for
ndirect comparison, superior to informal methods, as com-
arison of confidence intervals.
For these comparisons, we let HRAB and HRCB be the
reported hazard rate ratio of treatment A versus B and of
treatment C versus B. Observing that B is the common
reference comparator (warfarin), HRAC may be estimated as
RAC  HRAB/HRCB. A confidence interval was esti-
ated using the reported confidence intervals (CIl, CIu).
he standard error (SE) of log(HR) was estimated by:
(log(CIu)  log(CIl))/1.96, where 1.96 is the 97.5%
fractile of the standard normal distribution. The variance of
Summary of the Main Clinical Trials Involving Novel AnticoagulantsTable 1 Summary of the Main Clinical Trials Involving Novel An
Dabigatran (RE-LY)
Drug characteristics
Mechanism Oral direct thrombin inhibitor
Bioavailability, % 6
Time to peak levels, h 3
Half-life, h 12–17
Excretion 80% renal
Dose 150 mg BID
Dose in renal impairment 110 mg BID
Special considerations Intestinal absorption is pH dependent and is
reduced in patients taking proton pump
inhibitors.
Study characteristics
Study design Randomized open label
Number of patients 18,113
Follow-up period, months 24
Randomized groups Dose-adjusted warfarin vs. blinded doses of
dabigatran (150 mg BID, 110 mg BID)ARISTOTLE  Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; B
herapy; ROCKET-AF  Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin Klog(HRAC), (seAC)
2, is under independence given as
seAB)
2  (seCB)
2, and thus a 95% confidence interval of
HRAC is: exp(log(HRAC)  1.96  seAC). Reported p
alues are for the hypothesis H0:log(HRAC)  0 versus
HA:log(HRAC)  0, assuming log(HRAC) as normal
ith variance (seAC)
2.
The application of the method relies on a similarity
ssumption (11) that the hazard rate ratio HRAB was likely
also obtained if it was determined on the basis of the
population from which HRCB was estimated. Importantly,
he most direct way to consider this similarity assumption
alid is to require that the clinical studies be absolutely
omparable in terms of population characteristics and con-
uct of experiment (and as highlighted earlier, there are
ome differences between the trials—see Tables 1 and 2).
First, the expected effect of “any new anticoagulant”
versus warfarin was estimated as a weighted average using
the inverse of the variance of the log(HR) as weights.
Only results from the dabigatran 150 mg BID arm of the
RE-LY study was used in combination with data from
ARISTOTLE and ROCKET-AF to ensure independence
between the components of the average. No statistical
adjustments were made for multiple comparisons within this
study. The second focus in this analysis was the indirect
comparisons of apixaban versus dabigatran (both doses) and
rivaroxaban, as well as rivaroxaban versus dabigatran (both
doses). Direct comparisons of dabigatran 110 mg BID
versus dabigatran 150 mg BID were already available from
the RE-LY trial (3).
Baseline characteristics were tested for homogeneity be-
tween trials by reporting risk differences with 95% confi-
dence intervals for categorical data and normal distribution
2-sample comparison with unequal variances for continuous
troke Prevention in Nonvalvular AFgulants for Stroke Prevention in Nonvalvular AF
Rivaroxaban (ROCKET-AF) Apixaban (ARISTOTLE)
irect factor Xa inhibitor Oral direct factor Xa inhibitor
60–80 50
3 3
5–9 9–14
ver, 1/3 renal 25% renal, 75% fecal
g OD 5 mg BID
g OD (if creatinine clearance 30–49 ml/min) 2.5 mg BID
r levels expected in patients with renal or
atic failure.
ty lower in fasted patients, so should be
en after food.
enter, randomized, double-blind,
ble-dummy
Randomized control, double-blind,
parallel arm
14,264 18,201
40 40
adjusted warfarin vs. rivaroxaban 20 mg OD Dose-adjusted warfarin vs.
apixaban 5 mg BIDfor Sticoa
Oral d
2/3 li
20 m
15 m
Highe
hep
Activi
tak
Multic
dou
Dose-ID  twice daily; OD  once daily; RE-LY  Randomized Evaluation of Long-Term Anticoagulant
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.
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August 21, 2012:738–46 New Oral Anticoagulant Drugs in AFdata. Stata 11.2 (StataCorp LP, College Station, Texas), R
v2.12.1 (R Foundation for Statistical Computing, Vienna,
Austria), and Microsoft Excel 2003 (Redmond, Washing-
ton) for Windows were used for the statistical analyses and
graphical presentation.
Results
The clinical trials being compared for this analysis are
summarized in Table 1, with their primary safety and
efficacy endpoints summarized in Online Table 2.
Summary patient characteristics and risk differences
(with confidence intervals) are presented for the entire
study population in Table 2. As expected, there were
important differences between the studies, particularly for
the CHADS2 score (50 percentage point difference
between ROCKET-AF and the other trials) and the pro-
portion of secondary prevention (approximately 35 percent-
age point difference between ROCKET-AF and the other
trials). Mean/median age was broadly similar, as were the
proportions of female patients. There were more patients
with paroxysmal AF in RE-LY (36.4%) compared with
ROCKET-AF and ARISTOTLE (approximately 15 to 17
percentage point difference). The prevalence of prior heart
failure, diabetes, and hypertension was highest in
ROCKET-AF (62.5%, 40%, and 90.5%, respectively) com-
pared with the other 2 trials. Prior warfarin use was 62.4% in
ROCKET-AF, compared with 50% in RE-LY (by design)
and 57% in ARISTOTLE. The proportions with prior MI
and prior aspirin use were broadly similar in the 3 trials.
When data with dabigatran 150 mg BID were used for
the weighted average effects analysis, the new OACs as a
whole were associated with lower stroke or systemic embo-
lism (21%, p  0.001), lower stroke (23% p  0.001), and
Risk Differences and Confidence Intervals, in Relation to DifferenceTable 2 Risk Differences and Confidence Intervals, in Relation
Baseline Characteristics
RE-LY
(N  18,113)
ROCKET-AF
(N  14,264)
ARISTOTLE
(N  18,201
Age, yrs* 71.5 8.7 73 [65–78] 70 [63–76]
Female, % 36.4 39.7 35.2
CHADS2, mean 2.2 3.5 2.1
CHADS2 3–6, % 32.5 87.0 30.2
Paroxysmal AF, % 32.8 17.6 15.3
Prior stroke, TIA,
or systemic embolism, %
20.0 54.8 19.4
Heart failure, % 32.0 62.5 35.4
Prior myocardial infarction, % 16.6 17.3 14.2
Diabetes, % 23.3 40.0 25.0
Hypertension, % 78.9 90.5 87.5
Medication
Aspirin, % 39.8 36.5 30.9
Vitamin K antagonist, % 49.6 62.4 57.2
*Values for RE-LY: mean  SD; for ROCKET-AF and ARISTOTLE: median [interquartile range].
AF  atrial fibrillation; TIA  transient ischemic attack; other abbreviations as in Table 1.ower hemorrhagic stroke (53%, p  0.001) than warfarin. lll-cause mortality was lower for any new OAC (by 12%,
 0.001). Major and intracranial bleeding were lower for
ny new OAC by 13% (p  0.001) and 51% (p  0.001)
espectively. Weighted average hazard ratio and confidence
ntervals are given in Table 3.
Hazard rate ratio point estimates and 95% confidence
ntervals for the main trial endpoints for all indirect com-
arisons using warfarin as a common comparator are shown
n Table 4 and Figures 1 and 2.
elative efficacy of dabigatran, apixaban, and rivaroxaban.
here was a significantly lower risk of stroke and systemic
mbolism (by 26%) for dabigatran (150 mg BID) compared
ith rivaroxaban, as well as less hemorrhagic stroke (by
6%, p  0.039) and nondisabling stroke (by 40%, p 
.038). There were no significant differences for apixaban
ersus dabigatran (both doses) or rivaroxaban, or rivaroxa-
an versus dabigatran 110 mg BID, in preventing stroke and
ystemic embolism. For the ischemic stroke endpoint, there
ere no significant differences between the new OACs.
elative safety of dabigatran, apixaban, and rivaroxaban.
ajor bleeding was significantly lower with apixaban com-
ared with dabigatran 150 mg BID (by 26%, p  0.003)
nd rivaroxaban (by 34%, p  0.001), but was not
ignificantly different from dabigatran 110 mg BID
Table 4, Fig. 1). Gastrointestinal and extracranial bleed-
ng was also significantly less with apixaban compared
ith dabigatran 150 mg BID, by 41% (p  0.003) and
6% (p  0.007), respectively. There were no significant
ifferences between apixaban and dabigatran 110 mg BID
n safety endpoints.
Apixaban also had lower major or clinically relevant
leeding (by 34%, p  0.001) compared with rivaroxaban.
here was an increase (278%, p  0.027) in systemic
mbolism for apixaban compared with rivaroxaban with
the Study Populations at Baselinefferences in the Study Populations at Baseline
RE-LY vs. ROCKET-AF
RE-LY vs. ARISTOTLE
Percent Point
(% Study 1; % Study 2)
ROCKET-AF vs. ARISTOTLE
Percent Point
(% Study 1; % Study 2)
— — —
3.3 (4.3;2.2) 1.1 (0.2; 2.2) 4.5 (3.3; 5.5)
1.26 (1.28;1.23) 0.1 (0.08; 0.12) 1.36 (1.34; 1.38)
54.5 (55.3;53.6) 2.2 (1.3; 3.2) 56.7 (55.9; 57.6)
15.2 (14.3; 16.1) 17.5 (16.6; 18.4) 2.3 (1.5; 3.1)
34.8 (35.8;33.8) 0.6 (0.03; 1.4) 35.3 (43.3; 36.3)
30.5 (31.5;29.4) 3.5 (4.4;2.5) 27.0 (26.0; 28.1)
0.7 (1.5; 0.1) 2.4 (1.6; 3.1) 3.1 (2.3; 3.9)
16.6 (17.6;15.6) 1.7 (2.6;0.8) 14.9 (13.9;16.0)
11.7 (12.4;10.9) 8.6 (9.4;7.8) 3.1 (2.9; 3.7)
3.3 (2.2; 4.3) 8.8 (7.8; 9.8) 5.5 (4.5; 6.6)
12.8 (13.9;11.7) 7.5 (8.5;6.5) 5.3 (4.2; 6.3)s into Di
)






ower bound of 95% confidence interval at 16% increase.
Throm
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New Oral Anticoagulant Drugs in AF August 21, 2012:738–46Gastrointestinal bleeds were only reported numerically in
ROCKET-AF and therefore not used in this analysis.
When compared with rivaroxaban, dabigatran 110 mg
BID was associated with less major bleeding (by 23%,
p  0.011) and intracranial bleeding (by 54%, p  0.006)
(Table 4, Fig. 2).
Our indirect comparison analysis did not find any
significant differences in MI events between dabigatran
(both doses) and apixaban but more MI events were seen
with dabigatran (50%) compared to rivaroxaban (Table 4,
Fig. 2).
Weighted Average Effects of New OAC Versus WarfarinTable 3 Weighted Average Effects of New OAC Versus Warfarin
Any NOAC (Dabigatran 110
Apixaban, Rivaroxaban) vs.
Weighted Average
Effect HR
95% CI
Lower
9
Stroke or systemic embolism 0.856 0.772
Stroke 0.847 0.756
Ischemic or uncertain type of stroke 0.983 0.866
Hemorrhagic stroke 0.485 0.373
Death from any cause 0.890 0.825
Myocardial infarction 0.953 0.810
ISTH major bleeding 0.831 0.765
Intracranial bleeding 0.465 0.378
Only endpoints available in all studies are reported.
BID  twice daily; CI  confidence interval; HR  hazard ratio; ISTH  International Society on
Indirect Comparison Using Warfarin as Single Common Comparatoron the Basis of the RE-LY, ROCKET-AF, a d ARISTOTLE TrialsTable 4 Indirect Comparison Using Warfarin as Si gle Comm non the Basis of the RE-LY, ROCKET-AF, and ARISTOTLE
Apixaban ¢
¡ Dabigatran 110
Apixaban ¢
¡ Dabigatran 1
HR 95% CI HR 95% C
Efficacy endpoints
Stroke or systemic embolism 0.88 (0.67–1.15) 1.22 (0.91–1.
Stroke 0.86 (0.65–1.14) 1.23 (0.92–1.
Ischemic or uncertain type of
stroke
0.83 (0.61–1.13) 1.21 (0.88–1.
Hemorrhagic stroke 1.65 (0.81–3.34) 1.96 (0.94–4.
Systemic embolism NA NA
Nondisabling stroke NA NA
Mortality endpoints
Death from any cause 0.98 (0.83–1.16) 1.01 (0.85–1.
Death from vascular causes NA NA
Other endpoints
Myocardial infarction 0.68 (0.45–1.03) 0.69 (0.46–1.
Pulmonary embolism 0.62 (0.17–2.20) 0.48 (0.14–1.
Bleeding endpoints
Major bleeding 0.86 (0.7–1.06) 0.74 (0.61–0
Major or clinically relevant
nonmajor bleeding
NA NA
Life-threatening bleeding NA NA
Intracranial bleeding 1.35 (0.79–2.32) 1.05 (0.63–1.
Gastrointestinal bleeding 0.81 (0.57–1.15) 0.59 (0.42–0
Extracranial or unclassified
bleeding
0.84 (0.67–1.05) 0.74 (0.59–0
See Online Table 1 for availability and endpoint definition in original study. How to read: Drug A ¢¡
via 1 common comparator, warfarin (A ¢¡ warfarin ¢¡ B). Comparisons with HR  1.00 outside 95%
NA  not available; other abbreviations as in Table 2.Discussion
In this indirect comparison analysis, the new OACs as a
whole resulted in a lower risk of stroke or systemic embo-
lism, stroke, hemorrhagic stroke, and all-cause mortality
compared with warfarin, Also, major and intracranial bleed-
ing were lower for any new OAC.
Notwithstanding the limitations of an indirect compari-
son study, this analysis shows that there were no significant
differences for apixaban versus dabigatran (both doses) or
rivaroxaban; or between rivaroxaban versus dabigatran
D,
rin
Any NOAC (Dabigatran 150 mg BID,
Apixaban, Rivaroxaban) vs. Warfarin
p Value
Weighted Average
Effect HR
95% CI
Lower
95% CI
Upper p Value
0.003 0.793 0.714 0.881 0.000
0.004 0.769 0.684 0.864 0.000
0.788 0.878 0.771 1.000 0.051
0.000 0.474 0.363 0.619 0.000
0.003 0.880 0.815 0.950 0.001
0.557 0.949 0.807 1.116 0.525
0.000 0.875 0.806 0.950 0.001
0.000 0.490 0.400 0.601 0.000
bosis and Haemostasis; OAC  oral anticoagulation therapy.
parator,
ls
Apixaban ¢
¡ Rivaroxaban
Dabigatran 110 ¢
¡ Rivaroxaban
Dabigatran 150 ¢
¡ Rivaroxaban
HR 95% CI HR 95% CI HR 95% CI
0.90 (0.71–1.13) 1.02 (0.79–1.32) 0.74 (0.56–0.97)
0.93 (0.71–1.22) 1.08 (0.81–1.44) 0.75 (0.56–1.02)
0.98 (0.72–1.33) 1.18 (0.86–1.62) 0.81 (0.58–1.13)
0.86 (0.48–1.57) 0.53 (0.25–1.12) 0.44 (0.20–0.96)
3.78 (1.16–12.31) NA NA
NA 0.83 (0.53–1.32) 0.60 (0.37–0.97)
1.05 (0.84–1.30) 1.07 (0.85–1.34) 1.04 (0.82–1.30)
NA 1.01 (0.78–1.31) 0.96 (0.74–1.24)
1.09 (0.74–1.60) 1.59 (1.07–2.37) 1.57 (1.05–2.33)
NA NA NA
0.66 (0.54–0.81) 0.77 (0.63–0.94) 0.89 (0.73–1.09)
0.66 (0.58–0.75) NA NA
NA 1.36 (0.82–2.27) 1.62 (0.97–2.70)
0.63 (0.39–1.01) 0.46 (0.27–0.80) 0.60 (0.35–1.01)
NA NA NA
NA NA NA
, HR1.00 means hazard risk of Drug A is smaller than hazard risk of Drug B, indirectly comparedmg BI
Warfa
5% CI
Upper
0.948
0.949
1.116
0.632
0.961
1.120
0.902
0.572,Com
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I
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confidence interval are in boldface. The bold values indicate significant values.
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although dabigatran 150 mg BID was superior to rivaroxa-
ban for preventing stroke and systemic embolism, hemorrhagic
stroke, and nondisabling stroke. There were no differences be-
tween the new OACs in the ischemic stroke endpoint.
We found no significant differences between dabigatran
110 mg BID and apixaban in the main safety endpoints.
Favors Apixa
EFFICACY ENDPOINTS
MORTALITY ENDPOINTS
OTHER ENDPOINTS
BLEEDING ENDPOINTS
Stroke or systemic embolism
Stroke
Ischemic or uncertain type of stroke
Hemorrhagic stroke
Systemic embolism
Nondisabling stroke
Death from any cause
Death from vascular causes
Myocardial infarction
Pulmonary embolism
Major bleeding
Major or CRNM bleeding
Life-threatening bleeding
Intracranial bleeding
Gastrointestinal bleeding
Extracranial or unclassified bleeding
0.2 0.5
Figure 1 Apixaban Versus Dabigatran 110 mg BID, Dabigatran
The plot shows the relative risk and 95% confidence interval of each outcome with apixab
CRNM  clinically relevant non-major bleeding.When compared with dabigatran 150 mg BID, apixabanhad significantly less major bleeding and gastrointestinal
bleeding, but there were no significant differences between
apixaban and dabigatran 110 mg BID in the safety endpoints.
When compared with rivaroxaban, apixaban had lower major
bleeding, whereas dabigatran 110 mg BID was associated with
less major bleeding and lower intracranial bleeding.
The indirect comparison using a common comparator
        Favors alternative
Dabigatran 110
Dabigatran 150
Rivaroxaban
Dabigatran 110
Dabigatran 150
Rivaroxaban
Dabigatran 110
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Dabigatran 110
Dabigatran 150
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clinical trials with these new agents (8). Such a trial would
require huge numbers of study subjects to demonstrate
noninferiority, especially in a broad group of AF patients
with 1 stroke risk factors and given that overall stroke
ates may be declining (12,13).
In the RE-LY trial, which did directly compare dabiga-
Favors alternativ
EFFICACY ENDPOINTS
MORTALITY ENDPOINTS
OTHER ENDPOINTS
BLEEDING ENDPOINTS
Stroke or systemic embolism
Stroke
Ischemic or uncertain type of stroke
Hemorrhagic stroke
Systemic embolism
Nondisabling stroke
Death from any cause
Death from vascular causes
Myocardial infarction
Pulmonary embolism
Major bleeding
Major or CRNM bleeding
Life-threatening bleeding
Intracranial bleeding
Gastrointestinal bleeding
Extracranial or unclassified bleeding
0.2 0.5
Figure 2 Rivaroxaban Versus Apixaban, Dabigatran 110 mg BID
The plot shows the relative risk and 95% confidence interval of each outcome with
Abbreviations as in Figure 1.ran 110 mg BID against dabigatran 150 mg BID (and both sagainst warfarin), there was a significant reduction in the
primary endpoint of stroke and systemic embolism with
dabigatran 150 mg BID over dabigatran 110 mg BID
(relative risk: 0.73, 95% confidence interval: 0.58 to
0.91, p  0.001) (3). Even for ischemic stroke, where this
ndpoint was significantly reduced compared with warfarin
n the RE-LY trial per se, the present analysis does not
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rivaroxaban, or even rivaroxaban versus dabigatran (both
doses). Nonetheless, dabigatran 150 mg BID did appear to
have significantly less hemorrhagic stroke and nondisabling
stroke compared with rivaroxaban.
Bleeding is clearly an endpoint of concern in anticoagu-
lated AF patients (14). The present analysis clearly shows
significantly lower major bleeding rates with apixaban com-
pared with dabigatran 150 mg BID and rivaroxaban, and a
nonsignificant difference between apixaban and dabigatran
110 mg BID. In the ARISTOTLE trial, major bleeding
was 31% lower with apixaban compared with warfarin, and
our observations in the present analysis would be consistent
with this. For the endpoint of major and clinically relevant
nonmajor bleeding, apixaban also did better than rivaroxa-
ban. Of note, major bleeding with dabigatran 110 mg BID
was not significantly different from apixaban, but signifi-
cantly less (as was intracranial bleeding) when compared
with rivaroxaban.
Bleeding risk in AF is multifactorial (14), and indeed, the
addition of apixaban to antiplatelet therapy in the setting of
acute coronary syndromes resulted in a significant increase
in major bleeding with no evidence of efficacy (15). In the
setting of acute coronary syndromes, a low-dose (2.5 mg
and 5.0 mg), twice-daily regime of rivaroxaban resulted in a
significant reduction in the primary endpoint (a composite
of death from cardiovascular causes, MI, or stroke) com-
pared with placebo among patients taking dual antiplatelet
therapy, at the cost of more major bleeding events and
intracranial hemorrhage (16).
Another safety endpoint of concern in the AF trials was
a numerical increase in MI events in the RE-LY trial
(0.8%/year with dabigatran compared with warfarin, 0.6%/
year), and this indirect comparison analysis did not show
any statistically significant differences in MI events between
dabigatran (both doses) and apixaban. However, our indi-
rect comparison analysis found both doses of dabigatran
were associated with 50% more MI events compared to
rivaroxaban but this needs to be put in context of the low
absolute rates and the positive net clinical benefit overall of
using these new drugs. A recent detailed analysis from
RE-LY found that whereas MI events were numerically
increased, other myocardial ischemic events were not (17).
Also, the relative effects of dabigatran versus warfarin on
myocardial ischemic events were consistent in patients with
or without a baseline history of MI (17). Of note, vascular
mortality was significantly reduced with dabigatran 150 mg
BID compared with warfarin in the RE-LY trial (3). One
meta-analysis was suggestive of a significant increase in MI
events with dabigatran use in various different clinical trials
for AF, acute coronary syndromes, and venous thromboem-
bolism, although total mortality was significantly less with
dabigatran versus comparator (18).
Study limitations. This indirect comparison addresses the
main efficacy and safety endpoints reported in the trials, and
the fundamental challenges for such an approach are as dfollows: 1) the differences in patient population; 2) differ-
ences in definition of major bleeding; and 3) unblinded
versus nonblinded/double-blinded comparisons. Indeed,
deviations from similarity are potentially more confounding
in this approach than in a traditional meta-analysis. How-
ever, major bleeding and major plus clinically relevant
nonmajor bleeding were all defined by ISTH criteria. Also,
“stroke and systemic embolism” is a standardized primary
endpoint for clinical trials of stroke prevention in AF (19).
Other adverse effects, such as dyspepsia, were not compared,
although this was increased with dabigatran compared with
warfarin in the RE-LY trial (3).
Clearly, there are a number of constraints and limitations
related to the method used for an indirect comparison
analysis, but this is still considered a reasonable statistical
tool to qualify a comparison of effects that have not yet been
investigated head to head. The method and its usage, pros,
and cons have been the subject of many papers in recent
years, and is an accepted technique and method (8,10,20).
Another limitation is that this analysis cannot adjust for
patient demography and stroke risk of the different trial
populations, and some differences are evident (Tables 1 and 2,
nline Table 2), with, e.g., ROCKET-AF studying a higher-
isk population. Furthermore, we cannot account for differ-
nces in warfarin control between the trials, with mean time in
herapeutic range in the RE-LY and ARISTOTLE trials
eing much better than that seen in the ROCKET-AF trial.
n alternative technique to the Bucher method used in this
aper would be a network-based indirect comparison, which is
Bayesian Markov chain Monte Carlo method. The latter has
ts strengths in situations where there are many trials and with
rials that have several treatment arms. We feel that in this
articular setting with only 3 trials, each with its own treat-
ent, that the Bucher method was preferred because it is much
ore simple and transparent method. Differences in inclu-
ion and exclusion criteria, patient population, data
ollection methods, and outcome definitions or adjudi-
ation may result in residual confounding and persisting
eterogeneity. Indeed, the statistical technique used
omewhat assumes that the patients entered in the
arious trials and the level of anticoagulation were com-
arable.
Also, although all patients had AF, the risk of stroke and
erhaps other endpoints differed between trials, and no
tatistical adjustments were made for multiple comparisons
ithin this study. Finally, we have only used data from the
ublished phase III trials for this analysis, and there is still
large ongoing trial with the oral Factor Xa inhibitor
doxaban in AF, which has yet to report (21).
onclusions
otwithstanding the limitations of an indirect comparison
tudy, we found no profound significant differences in
fficacy between apixaban and dabigatran etexilate (both
oses) or rivaroxaban. Dabigatran 150 mg BID was superior
746 Lip et al. JACC Vol. 60, No. 8, 2012
New Oral Anticoagulant Drugs in AF August 21, 2012:738–46to rivaroxaban for efficacy (with less stroke and systemic
embolism and hemorrhagic stroke). Major bleeding was
significantly lower with dabigatran 110 mg BID or apixa-
ban. Only a head-to-head direct comparison of the different
new OACs would fully answer the question of efficacy/
safety differences between the new drugs for stroke preven-
tion in AF.
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